Lv3
206 积分 2025-10-24 加入
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
5天前
已关闭
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
5天前
已完结
Structural determinants of dual incretin receptor agonism by tirzepatide
5天前
已关闭
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
5天前
已完结
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
5天前
已完结
Structural determinants of dual incretin receptor agonism by tirzepatide
5天前
已完结
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
5天前
已完结
Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
11天前
已完结
Current therapeutic landscape and future treatment perspectives of MASH
19天前
已完结
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
20天前
已完结
皖公网安备34019202002308
